UBE2Q1 and breast carcinoma: Considering etiological similarities in ovarian and breast cancer, we compared expression of UBE2Q1 in different breast cancer subtypes and observed highest expression in most aggressive basal-like breast cancer patients, which are essentially negative for HER2 and estrogen receptors.